DXC Technology Named a Leader in Everest Group’s Life Insurance and Pensions Report
DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services provider, has been named a Leader by research firm Everest Group in its PEAK Matrix® for Life and Pensions Insurance Business Process Services/Third Party Administrators Service Provider 2022 report.
DXC provides a range of solutions to the insurance industry including business process services (BPS) and insurance software. It also serves as a licensed third-party administrator (TPA) in the U.S. and licensed broker-dealer in Canada, using its deep expertise in compliance and regulation.
The report acknowledged DXC’s position in the life insurance and pensions market with its highest designated category, noting the following:
- DXC has reaffirmed its commitment to the life and pensions (L&P) space through its strategic BPS focus, leveraging its differentiated ownership of the technology stack and especially its policy administration platforms.
-
DXC has augmented its platform-led approach and is aggressively taking its DXC Assure for Life and Wealth platform to the market, especially for new (policy) blocks and new product launches, and is experiencing good deal momentum. Additionally, DXC Assure’s integration with both proprietary and partner/insurtech solutions further strengthens this value proposition.
-
DXC has firmed up its presence to service new/active blocks, while simultaneously focusing on large closed-block deals where it already holds significant experience and has invested in modernizing conversion methodologies.
- DXC has expanded its North American footprint through strategic BPS wins in Canada.
“Recognizing DXC as a Leader and giving us high marks for our vision and strategy reinforces the strength of our insurance services and platform-led approach,” said Ray August, president, Insurance Software and Business Process Solutions. “We will continue to invest in our life and wealth solutions, helping our customers bridge from the old to the new to better serve their customers and grow market share.”
“DXC has continued to maintain a strong position in the L&P insurance BPS/third-party administrator (TPA) market, with its large and expanding clientele, commitment to developing IT/BPS synergies through its proprietary BPaaS capabilities, and end-to-end scope of services,” said Somya Bhadola, Practice Director, Everest Group. “A balanced and customized strategic approach across new, active and closed blocks demonstrates DXC’s commitment to this market and positions it as a Leader.”
This Everest Group report assessed 20 providers based on their vision, capabilities and market impact across North America, and categorized them as Leaders, Major Contenders or Aspirants. DXC was one of only five Leaders, a position the company has held for the past 7 years when the report launched.
A custom version of the Everest Group PEAK Matrix® for Life and Pensions (L&P) Insurance BPS/TPA Service Provider 2022 is available here. DXC was also recently recognized by Everest as a Leader in its Cloud Services PEAK Matrix Assessment 2022.
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. The world’s largest companies and public sector organizations trust DXC to deploy services across the Enterprise Technology Stack to drive new levels of performance, competitiveness, and customer experience. Learn more about how we deliver excellence for our customers and colleagues at DXC.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005398/en/
Contact information
Frank Hurteau
Corporate Media Relations
+1 (703) 582 4665
> Email
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AdvanCell to Present Promising Clinical Trial Results of ADVC001, a Novel Lead-212-based PSMA-targeted Alpha Therapy for Prostate Cancer, at ESMO 202513.10.2025 02:31:00 EEST | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, announces a presentation at the European Society for Medical Oncology (ESMO) Congress, taking place in Berlin, Germany, from October 17-21, 2025. The presentation will feature promising results from the Phase 1b dose escalation of the Phase 1/2 TheraPb study, evaluating ADVC001, a Lead-212-based PSMA-targeted alpha therapy, in metastatic castration-resistant prostate cancer (mCRPC). This will be the first presentation of clinical data from a 212Pb-PSMA therapy at a major oncology conference – an important milestone in advancing targeted alpha therapies for prostate cancer and a clear demonstration of AdvanCell’s leadership in radioligand therapy. The abstract presents a favorable safety profile for 212Pb-ADVC001 and promising anti-tumor activity, underscoring the potential of 212Pb-ADVC001 to enhance therapeutic options for patients with metastatic prostate cancer. The abs
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 202513.10.2025 01:05:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that results from Phase 1 proof-of-concept studies of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, and INCB161734, a novel, selective and orally bioavailable KRAS G12D inhibitor, will be highlighted as oral presentations at the upcoming European Society of Medical Oncology (ESMO) Congress 2025 in Berlin. “We are encouraged by the positive findings being presented with our TGFβR2×PD-1 and KRAS G12D inhibitor programs, which validate our rationale for advancing the development of these novel investigational compounds," said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. "There remains a significant need for new treatment options for patients with advanced solid tumors like colorectal cancer and pancreatic ductal adenocarcinoma and we look forward to providing updates on these clinical development programs.” Details on INCA33890 and INCB161734 oral presentations at ESMO include: INCA33890 (PD-1/TGFβR
Day Two of the 11th World FZO Congress Highlights the Role of Digitization and Sustainability in Shaping the Future of Free Zones11.10.2025 17:52:00 EEST | Press release
The World Free Zones Organization’s 11th annual World Congress continued its agenda today with a focus on the role of digitization and sustainability in the future of free zones and the mechanisms for enhancing their position as strategic trade gateways. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251011933300/en/ Dr Al Zarooni and President of CIRD launching the global institute (Photo: AETOSWire) The day’s sessions featured a series of sessions addressing critical themes such as the digitization of trade corridors, the impact of the OECD Global Minimum Tax, and the role of free zones as regional trade gateways. Sustainability took centre stage with sessions focusing on the transition to net-zero through renewable energy, circular economy models, and green financing frameworks. Speakers underscored that decarbonization is not only a climate imperative but also a competitive advantage for the next generation of free zones
IonQ to Participate in GITEX Dubai 2025, Showcasing Advancements in Quantum Infrastructure and Security10.10.2025 23:05:00 EEST | Press release
IonQ (NYSE: IONQ), a leading quantum company, today announced its participation in GITEX Global 2025, one of the world’s largest and most influential technology exhibitions, taking place October 13-17 at the Dubai World Trade Centre. IonQ executives and partners will highlight advancements in quantum computing, secure infrastructure, and commercial applications that are accelerating enterprise adoption of quantum technologies. Rima Alameddine, Chief Revenue Officer at IonQ, will speak on the panel “Cracking the Quantum Code: How to Build a Profitable Business in the Quantum Economy,” on October 14, in Hall 10, AI stage. This session will convene global quantum leaders to discuss the path from breakthrough science to viable commercial success, including how to unlock investment, scale quantum solutions, and deliver near-term value across sectors. Grégoire Ribordy, Co-founder and CEO at ID Quantique, an IonQ company, will also speak on October 16 during the panel “Establishing Quantum-Sa
IonQ to Participate in ComoLake2025, Advancing Quantum Collaboration in Italy10.10.2025 23:05:00 EEST | Press release
IonQ (NYSE: IONQ), a leading quantum company, today announced its participation in the ComoLake2025 Digital Innovation Forum, one of Italy’s most prominent technology events focused on digital transformation, infrastructure, and innovation policy. At ComoLake2025, taking place October 14–17 at the Villa Erba International Exhibition and Congress Center in Cernobbio, Niccolò de Masi, Chairman and CEO at IonQ, will deliver a special address, offering strategic insights into how quantum computing is reshaping infrastructure, industry, and Europe’s digital leadership. Marco Pistoia, Senior Vice President of Industry Relations at IonQ, will participate in the round table “Pan-European Quantum Industry Forum - Dialogue between Industry, Politics, and Research for Europe's Quantum Leadership” focused on strengthening Europe’s position in the global quantum landscape. Organized by the Fondazione Innovazione Digitale, ComoLake2025 is a four-day forum that draws over 1,400 participants and 215 s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom